BD AbSeq Assay
Becton Dickinson has announced the commercial release of its BD AbSeq assay, which will analyze protein expression at the single-cell level using high-throughput sequencing. The assay integrates high-quality antibodies from the BD Pharmingen portfolio with oligonucleotides, allowing researchers to perform single-cell analysis on the firm's Rhapsody single-cell analysis system. When used in tandem, the tools allow researchers to simultaneously analyze RNA and proteins in thousands of individual cells and develop a clearer picture of the role genes and proteins play in biological systems.
MedTek21 Version 4.0
MedTek21 has introduced version 4.0 of its eponymous medication management platform for precision medicine, which includes drug-to-gene monitoring. The new release adds reporting for patients at risk for harmful pharmacogenomic interactions as well as real-time alerts either through electronic health records systems or a standalone application. MedTek21 version 4.0 also features two-way integration with Epic Systems and Cerner EHRs and several popular pharmacy information systems.
Enpicom ImmunoGenomix Platform
Dutch bioinformatics software engineering company Enpicom has released the first version of its ImmunoGenomix platform to support the development of immunotherapies, as well as patient stratification and treatment monitoring. The firm will expand the platform into a comprehensive immunosequencing data analysis platform designed to analyze, monitor, and compare the immune repertoires in the context of immunotherapy development and at all stages of treatment and disease over time. The platform will enable customers to use their own sample preparation protocols and preferred next-generation sequencing technology.
For more new products and services, please visit the New Products page on our website.